



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 January 2019
EMA/CAT/38789/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Agenda for the meeting on 23-25 January 2019

23 January 2019, 14:00 – 18:30, room 02-F

24 January 2019, 09:00 – 18:00, room 02-F

25 January 2019, 09:00 – 12:00, room 02-F

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
1.4.	Technical information	5
2.	Evaluation of ATMPs	5
2.1.	Opinions.....	5
2.2.	Oral explanations.....	5
2.3.	Day 180 list of outstanding issues.....	5
2.4.	Day 120 list of questions	5
2.4.1.	Autologous CD34+ cells transduced with a lentiviral vector encoding the human β A-T87Q-globin gene (LentiGlobin-BB305) – Orphan – EMA/H/C/0003691	5
2.5.	Day 80 assessment reports.....	5
2.5.1.	Onasemnogene abeparvovec - Orphan - EMA/H/C/004750	5
2.6.	Update on ongoing initial applications.....	6
2.6.1.	Viable T-cells - Orphan - EMA/H/C/002397	6
2.7.	New applications.....	6
2.8.	Withdrawal of initial marking authorisation application.....	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004.....	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.11.1.	Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenoside deaminase (ADA) cDNA sequence - Orphan - EMA/H/C/003854/II/0016	6
2.11.2.	YESCARTA - axicabtagene ciloleucel - Orphan - EMA/H/C/004480/II/0003	6
2.12.	Other Post-Authorisation Activities	7
3.	Certification of ATMPs	7
3.1.	Opinion	7
3.2.	Day 60 Evaluation Reports.....	7
3.3.	New Applications	7
4.	Scientific Recommendation on Classification of ATMPs	7
4.1.	New requests – Appointment of CAT Coordinator.....	7
4.1.1.	Recombinant adeno-associated viral vector serotype-5 expressing human 21-hydroxylase gene – H0005295	7
4.1.2.	Autologous skeletal muscle derived cells attached to biodegradable poly(DL-lactide-co-glycolide) microparticles combined with skeletal muscle derived cells – H0005289.....	7

4.1.3.	Allogeneic, <i>ex vivo</i> expanded, umbilical cord (UC) blood-derived, haematopoietic CD34+ progenitor cells and allogeneic, non-expanded, UC blood-derived, haematopoietic mature myeloid and lymphoid cells - H0005288	7
4.1.4.	<i>In vitro</i> transcribed single-stranded messenger RNA (mRNA) molecules encoding human interferon- α 2b, interleukin-12, interleukin-15sushi, and Granulocyte-macrophage colony-stimulating factor – H0005291	8
4.1.5.	Allogeneic cord blood mononuclear cells - H0005292	8
4.1.6.	Recombinant adeno-associated viral vector (AAV) containing a human micro-dystrophin gene drug substance – H0005293	8
4.1.7.	DNA plasmid vector expressing interleukin -12 gene – H0005294	8
4.1.8.	<i>Ex vivo</i> expanded allogeneic bone marrow derived mesenchymal stromal cells – H0005290	8
4.2.	Day 30 ATMP scientific recommendation	8
4.2.1.	Recombinant adeno-associated virus (serotype 5) containing the human retinal guanylate cyclase 1 (GUCY2D) gene – H0005261	8
4.2.2.	Autologous cord blood nucleated cells – H0005260	8
4.2.3.	Recombinant adeno-associated virus (serotype 0) containing the human α -L-iduronidase (hIDUA) gene - H0005258	9
4.2.4.	Cultured autologous adipose-derived stem cells - H0005257	9
4.2.5.	Recombinant adeno-associated virus serotype rh10 (AAVrh10) containing a transgene that encodes a microRNA (miRNA) targeting superoxide dismutase 1 (SOD1) messenger RNA (mRNA) - H0005259	9
4.3.	Day 60 revised scientific recommendation (following list of questions)	9
4.3.1.	Whole lipoaspirate containing viable autologous adipose-derived regenerative cells - H0005212	9
4.3.2.	Viable autologous adipose-derived regenerative cells combined with whole lipoaspirate - H0005213	9
4.3.3.	Viable autologous adipose-derived regenerative cells combined with whole lipoaspirate - H0005214	9
4.3.4.	Whole lipoaspirate containing viable autologous adipose-derived regenerative cells - H0005215	10
4.3.5.	Viable autologous adipose-derived regenerative cells - H0005216	10
4.3.6.	Viable autologous adipose-derived regenerative cells - H0005217	10
4.4.	Finalisation of procedure	10
4.4.1.	Bacteriophage capsid containing deoxyribonucleic acid (DNA) encoding a ribonucleic acid (RNA)-guided nuclease and associated RNA guides, targeting shiga-toxin genes - H000523710	
4.4.2.	Allogeneic expanded natural killer (NK) cells – H0005241	10
4.4.3.	Autologous modified CD34+ haematopoietic cells transduced with a lentiviral vector encoding for the CD18 β -subunit of human β 2 integrin - H0005238	10
4.4.4.	Allogeneic cultured postnatal thymus tissue-derived product - H0005239	10
4.4.5.	Autologous dendritic cell, electroporated with messenger ribonucleic acid (mRNA) encoding tumour antigen Wilms tumor (WT)-1 – H0005240	11
5.	Scientific Advice	11
5.1.	New requests – appointment of CAT Rapporteurs	11
5.2.	CAT reports	11

5.3.	List of Issues	11
5.4.	Finalisation of SA procedures	11
6.	Pre-Authorisation Activities	11
6.1.	Paediatric investigation plans.....	11
6.2.	ITF briefing meetings in the field of ATMPs.....	11
6.3.	Priority Medicines (PRIME) – Eligibility requests	11
6.3.1.	Month 0 - Start of the procedure	11
6.3.2.	Month 1 – Discussion of eligibility	11
6.3.3.	Month 2 – Recommendation of eligibility.....	11
6.3.4.	Ongoing support.....	12
7.	Organisational, regulatory and methodological matters	12
7.1.	Mandate and organisation of the CAT	12
7.1.1.	CAT membership	12
7.1.2.	Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, 13-14 June 2019	12
7.2.	Coordination with EMA Scientific Committees	12
7.2.1.	Committee for Medicinal Products for Human Use (CHMP)	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups.....	12
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)	12
7.4.	Cooperation within the EU regulatory network.....	12
7.5.	Cooperation with international regulators.....	12
7.5.1.	ATMP cluster teleconference with FDA, Health Canada and PMDA.....	12
7.6.	CAT work plan.....	13
7.7.	Planning and reporting.....	13
7.8.	Others.....	13
7.8.1.	Request from the European Commission for EMA’s opinion on the definitions of pharmacological, immunological, metabolic and medical diagnosis	13
7.8.2.	EMA implementation of the new medical device and <i>in vitro</i> diagnostic regulation.....	13
8.	Any other business	13
8.1.	Relocation of EMA to The Netherlands	13
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held on 23-25 January 2019. See January 2019 CAT minutes (to be published post February 2019 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 23-25 January 2019 meeting

1.3. Adoption of the minutes

CAT minutes for 05-07 December 2018 meeting

1.4. Technical information

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

2.4.1. Autologous CD34+ cells transduced with a lentiviral vector encoding the human β A-T87Q-globin gene (LentiGlobin-BB305) – Orphan – EMA/H/C/0003691

Bluebird bio France; Treatment of transfusion-dependent beta-thalassaemia (also referred to as beta-thalassaemia major).

Scope: Day 120 list of questions

Action: for adoption

2.5. Day 80 assessment reports

2.5.1. Onasemnogene abeparvovec - Orphan - EMA/H/C/004750

AveXis Netherlands B.V.; Treatment of spinal muscular atrophy (SMA)

Scope: Day 80 assessment report.

Action: for discussion

2.6. Update on ongoing initial applications

2.6.1. Viable T-cells - Orphan - EMEA/H/C/002397

Kiadis Pharma Netherlands B.V.; Adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease

Scope: request by the applicant for a second clock stop extension .

Action: for adoption

Oral Explanation took place on 12.09.2018. List of Outstanding Issues adopted on 14.09.18 and 25.05.2018. List of Questions adopted on 08.09.2017.

2.7. New applications

No items

2.8. Withdrawal of initial marking authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence - Orphan - EMEA/H/C/003854/II/0016

Orchard Therapeutics (Netherlands) BV

Rapporteur: Christiane Niederlaender, CHMP Coordinator: Greg Markey

Scope: Opinion

Quality:

Action: for adoption

2.11.2. YESCARTA - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0003

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Martina Weise

Scope: Opinion

Clinical: update of sections 4.8. and 5.1. of the SmPC to add information based on phase 1/2 multicentre study evaluating the safety and efficacy of KTE-C19 in subjects with refractory aggressive non-Hodgkin lymphoma (ZUMA-1), an addendum presenting 24-month analysis. The package leaflet has been updated accordingly. Furthermore, editorial changes have been introduced throughout the PI.

Action: for adoption

2.12. Other Post-Authorisation Activities

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Recombinant adeno-associated viral vector serotype-5 expressing human 21-hydroxylase gene – H0005295

Treatment of congenital adrenal hyperplasia

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.2. Autologous skeletal muscle derived cells attached to biodegradable poly(DL-lactide-co-glycolide) microparticles combined with skeletal muscle derived cells – H0005289

Treatment of faecal incontinence and anorectal malformation

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.3. Allogeneic, *ex vivo* expanded, umbilical cord (UC) blood-derived, haematopoietic CD34+ progenitor cells and allogeneic, non-expanded, UC blood-derived, haematopoietic mature myeloid and lymphoid cells - H0005288

Haematopoietic reconstitution of patients who are medically indicated for allogeneic hematopoietic stem cell transplantation

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.4. *In vitro* transcribed single-stranded messenger RNA (mRNA) molecules encoding human interferon- α 2b, interleukin-12, interleukin-15sushi, and Granulocyte-macrophage colony-stimulating factor – H0005291

Treatment of solid tumors

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.5. *Allogeneic cord blood mononuclear cells* - H0005292

Treatment of neurological disorders, autism spectrum disorders, cerebral palsy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.6. *Recombinant adeno-associated viral vector (AAV) containing a human micro-dystrophin gene drug substance* – H0005293

Treatment of patients with Duchene muscular dystrophy (DMD)

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.7. *DNA plasmid vector expressing interleukin-12 gene* – H0005294

Treatment of advanced melanoma

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.8. *Ex vivo expanded allogeneic bone marrow derived mesenchymal stromal cells* – H0005290

Treatment of graft-*versus*-host disease

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.2. **Day 30 ATMP scientific recommendation**

4.2.1. *Recombinant adeno-associated virus (serotype 5) containing the human retinal guanylate cyclase 1 (GUCY2D) gene* – H0005261

Treatment of inherited retinal disease caused by biallelic mutations in GUCY2D, including Leber congenital amaurosis type 1 (GUCY2D-LCA)

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. *Autologous cord blood nucleated cells* – H0005260

Treatment of paediatric brain damage, hypoxic-ischemic encephalopathy, cerebral palsy

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Recombinant adeno-associated virus (serotype 0) containing the human α -L-iduronidase (hIDUA) gene - H0005258

Treatment of mucopolysaccharidosis type I

Scope: ATMP scientific recommendation

Action: for adoption

4.2.4. Cultured autologous adipose-derived stem cells - H0005257

Treatment of urinary diversion in patients requiring radical cystectomy for the treatment of bladder cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.2.5. Recombinant adeno-associated virus serotype rh10 (AAVrh10) containing a transgene that encodes a microRNA (miRNA) targeting superoxide dismutase 1 (SOD1) messenger RNA (mRNA) - H0005259

Treatment of amyotrophic lateral sclerosis (ALS) due to mutations in SOD1 gene

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

4.3.1. Whole lipoaspirate containing viable autologous adipose-derived regenerative cells - H0005212

Treatment of progressive hemifacial atrophy (Parry-Romberg syndrome)

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.3.2. Viable autologous adipose-derived regenerative cells combined with whole lipoaspirate - H0005213

Treatment of progressive hemifacial atrophy (Parry-Romberg syndrome)

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.3.3. Viable autologous adipose-derived regenerative cells combined with whole lipoaspirate - H0005214

Treatment of progressive hemifacial atrophy (Parry-Romberg syndrome)

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.3.4. Whole lipoaspirate containing viable autologous adipose-derived regenerative cells - H0005215

Treatment of burn scars

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.3.5. Viable autologous adipose-derived regenerative cells - H0005216

Treatment of burn scars

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.3.6. Viable autologous adipose-derived regenerative cells - H0005217

Treatment of burn scars

Scope: assessment of the responses from the applicant. Revised ATMP scientific recommendation

Action: for adoption

4.4. Finalisation of procedure

4.4.1. Bacteriophage capsid containing deoxyribonucleic acid (DNA) encoding a ribonucleic acid (RNA)-guided nuclease and associated RNA guides, targeting shiga-toxin genes - H0005237

Treatment of Shiga-toxin producing *E. coli* (STEC) infection
Scope: the European Commission raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.2. Allogeneic expanded natural killer (NK) cells – H0005241

Treatment of multiple myeloma

Scope: the European Commission raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.3. Autologous modified CD34+ haematopoietic cells transduced with a lentiviral vector encoding for the CD18 β -subunit of human β 2 integrin - H0005238

Treatment of severe leukocyte adhesion deficiency type I (LAD-I)

Scope: the European Commission raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.4. Allogeneic cultured postnatal thymus tissue-derived product - H0005239

Immune reconstitution in patients with congenital athymia

Scope: the European Commission raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.5. Autologous dendritic cell, electroporated with messenger ribonucleic acid (mRNA) encoding tumour antigen Wilms tumor (WT)-1 – H0005240

Treatment of lung cancer

Scope: the European Commission raised no comments. Final ATMP scientific recommendation

Action: for information

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Czech Republic: Ondřej Palán - nominated as the new alternate from 01 January 2019

Norway: Maja Sommerfelt Grønvold - nominated as the new alternate from 01 January 2019

Action: for information

7.1.2. Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, 13-14 June 2019

CAT resources: Simona Badoi

Scope: initial topics for the agenda

Action: for discussion

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the December 2018 meeting

Action: for information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope:

PCWP: draft mandate and composition

HCPWP: draft mandate and composition

PCWP and HCPWP: draft rules of procedure

Action: for adoption

Scope: HCPWP: summary of the plenary meeting that took place on 26 September 2018

Action: for information

7.4. Cooperation within the EU regulatory network

None

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA

The teleconference will take place

CAT: Martina Schübler-Lenz

Scope: draft agenda

Action: for discussion

7.6. CAT work plan

None

7.7. Planning and reporting

None

7.8. Others

7.8.1. Request from the European Commission for EMA's opinion on the definitions of pharmacological, immunological, metabolic and medical diagnosis

CAT Sponsor: Margarida Menezes Ferreira: pharmacological
CAT Sponsors: Jan Mueller-Berghaus, Ilona Reischl: immunological
CAT Sponsor: Claire Beuneu: metabolic
CAT Sponsors: Paolo Gasparini, Giulio Pompilio: medical diagnosis

Scope: definitions of pharmacological, immunological, metabolic and medical diagnosis

Action: for discussion

7.8.2. EMA implementation of the new medical device and *in vitro* diagnostic regulation

CAT: Ilona Reischl

Scope: Identification of CAT members with medical device competence (establishment of CAT Medical Device Focus group).

Action: for discussion

8. Any other business

8.1. Relocation of EMA to The Netherlands

Action: for information

Date of next CAT meeting:

20-22/02/2019

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper
 RSI: Request for supplementary information
 SAs: Scientific Advices
 SAG-O: Scientific Advisory Group Oncology
 SAWP: Scientific Advice Working Party
 SR: Summary Report
 SWP: Scientific Working Party
 SME: Small and medium size enterprises
 SmPC: Summary of Products Characteristics
 TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that

are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/